

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON & BIRD LLP

3201 Beechleaf Court, Suite 600
Raleigh, NC 27604-1062
919-862-2200
Fax: 919-862-2260

RECEIVED
CENTRAL FAX CENTER

APR 06 2004

OFFICIAL

TELECOPY

PLEASE DELIVER AS SOON AS POSSIBLE

Date:

April 6, 2004

Recipient:

Examiner Phuong T. Bui, Crystal
Mall 1, Art Unit 1638

Company:

United States Patent and Trademark
Office

Fax Number:

(703) 872-9306

Voice Number:

(571) 272-0793

Sender:

David M. Saravitz

Message:

Re: U.S. Patent Application for OAR Polynucleotides, Polypeptides and Their Use in PHA
Production in Plants
Appl. No. 10/024,806, filed December 19, 2001

Number of Pages: (including cover page) **16**

IF NOT RECEIVED PROPERLY, PLEASE NOTIFY US IMMEDIATELY AT Marilyn Munoz.

USER CODE: SARAV	REQUESTED BY: Marilyn Munoz
CLIENT/MATTER: 035718/241887	OPERATOR:

OFFICIAL

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 10/024,806
Applicant(s): Zheng *et al.*
Filed: December 19, 2001
Art Unit: 1638
Examiner: Phuong T. Bui
Title: OAR POLYNUCLEOTIDES, POLYPEPTIDES AND
THEIR USE IN PHA PRODUCTION IN PLANTS

Confirmation No.: 6104

**RECEIVED
CENTRAL FAX CENTER**

APR 06 2004

Docket No.: 35718/241887 (5718-128)
Customer No.: 29122

April 6, 2004

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**AMENDMENT
37 C.F.R. § 1.121**

Sir:

In response to the Office Action dated December 19, 2003, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims beginning on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.

RTA01/2147789v1